Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00096174 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00096174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2005
Completion date
July 31, 2016
Enrollment
69 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer